Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/Ib trial of bavituximab in combination with durvalumab in patients with multiple solid tumors

Next Previous
Trial Profile

Phase I/Ib trial of bavituximab in combination with durvalumab in patients with multiple solid tumors

Status: Suspended
Phase of Trial: Phase I

Latest Information Update: 15 Mar 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bavituximab (Primary) ; Durvalumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions

    • Most Recent Events

    • 09 Mar 2016 According to a Peregrine Pharmaceuticals media release, status changed from planning to suspended.
    • 09 Mar 2016 According to a Peregrine Pharmaceuticals media release, due to setback development in the SUNRISE trial, the companies (Peregrine and AstraZeneca) are currently working together to identify the optimal path forward for demonstrating potential mechanistic synergies between bavituximab and durvalumab in different patient populations. The expected timing of initiation of this trial will be determined upon finalization of its trial design.
    • 10 Dec 2015 According to a company media release, Peregrine Pharmaceuticals expects to initiate this study in 2016.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top